



Eli Lilly Reports Q1 2026 Earnings Results

Description

Eli Lilly announced strong first-quarter earnings on Thursday, with revenue exceeding expectations. The demand for its weight loss drug Zepbound and diabetes treatment Mounjaro has risen significantly. This increase has prompted the company to revise its full-year sales forecast, now estimating revenue between \$82 billion and \$85 billion for 2026.

Mounjaro's global revenue increased by 125% to \$8.66 billion, with \$4.2 billion in U.S. sales. This was much higher than analyst predictions. Zepbound, introduced about three years ago, generated \$4.16 billion in U.S. sales, an 80% increase compared to last year. Both products contributed to Lilly's strong performance despite lower prices in the U.S.

The company holds a significant share of the GLP-1 drug market, which treats obesity and diabetes, with a 60.1% market share in the U.S. Analysts had expected lower earnings and revenue, but Lilly reported earnings of \$8.55 per share, higher than the anticipated \$6.66, and total revenue of \$19.80 billion.

Lilly's net income for the quarter was \$7.40 billion, compared to \$2.76 billion a year earlier. Their new GLP-1 pill, Foundayo, recently launched but is not included in these earnings. Analysts suggest its early sales performance has been modest. Lilly also anticipates gaining from Foundayo and increased Medicare coverage for obesity drugs but expects pricing pressures from various factors.

Vocabulary List:

1. **earnings** //ˈɜːnɪŋz// (noun): money a company earns in a period
2. **revenue** //ˈrevənu// (noun): money a company gets from sales or work
3. **demand** //dɪˈmænd// (noun): want for a product or service
4. **forecast** //ˈfɔːrkæst// (noun): a guess about future numbers or results
5. **modest** //ˈmɒdɪst// (adjective): not large in size or amount
6. **anticipates** //ænˈtɪsəˌpeɪts// (verb): expects something to happen or be received

Comprehension Questions

Multiple Choice



-
1. What is the estimated revenue range for Eli Lilly in 2026?
 - Option: \$70 billion to \$75 billion
 - Option: \$75 billion to \$80 billion
 - Option: \$82 billion to \$85 billion
 - Option: \$90 billion to \$95 billion
 2. What was the global revenue increase percentage for Mounjaro?
 - Option: 100%
 - Option: 110%
 - Option: 125%
 - Option: 150%
 3. How much did Zepbound generate in U.S. sales?
 - Option: \$4.16 billion
 - Option: \$5 billion
 - Option: \$3 billion
 - Option: \$2 billion
 4. What was Lilly's reported earnings per share?
 - Option: \$6.66
 - Option: \$8.55
 - Option: \$7.40
 - Option: \$5.50
 5. What market share does Lilly hold in the GLP-1 drug market in the U.S.?
 - Option: 50.1%
 - Option: 55.1%
 - Option: 60.1%
 - Option: 65.1%
 6. What is the total revenue reported by Lilly for the quarter?
 - Option: \$15.50 billion
 - Option: \$19.80 billion
 - Option: \$20 billion
 - Option: \$22 billion

True-False



7. Eli Lilly's revenue for Mounjaro was lower than analyst predictions.
8. Zepbound was introduced over five years ago.
9. Lilly's earnings per share exceeded \$8.
10. Foundayo is included in the earnings report.
11. Lilly's net income this quarter was higher compared to a year earlier.
12. Lilly expects pricing pressures from various factors.

Gap-Fill

13. Mounjaro's global revenue increased by _____ to \$8.66 billion.
14. Zepbound generated \$4.16 billion in U.S. sales, which is an _____ compared to last year.
15. Lilly's reported total revenue for the quarter was _____ billion.
16. Foundayo is a new GLP-1 pill that recently launched but is not included in these _____.
17. The demand for Eli Lilly's weight loss drug Zepbound has _____ significantly.
18. Lilly anticipates gaining from _____ and increased Medicare coverage for obesity drugs.

Answer

Multiple Choice: 1. \$82 billion to \$85 billion 2. 125% 3. \$4.16 billion 4. \$8.55 5. 60.1% 6. \$19.80 billion

True-False: 7. False 8. False 9. True 10. False 11. True 12. True

Gap-Fill: 13. 125% 14. 80% increase 15. 19.80 16. earnings 17. risen 18. Foundayo



Answer

CATEGORY

1. Business - LEVEL3

POST TAG

1. B1
2. earnings
3. Eli Lilly
4. ESL learning
5. esl news
6. L3
7. Level 3
8. Q1 2026

Tags

1. B1
2. earnings
3. Eli Lilly
4. ESL learning
5. esl news
6. L3
7. Level 3
8. Q1 2026

Date Created

2026/04/30

Author

aimeeyoung99

ESL-NEWS.COM